Bioventus rises after better-than-expected quarterly results

Shares of medical device maker Bioventus BVS.O rise 7.58% to $9.11 premarket

Co posts Q4 adjusted profit of 24 cents per share vs analysts' estimate of 22 cents per share, according to data compiled by LSEG

Posts Q4 net sales of $157.9 million vs analysts' estimate of $154.9 million

Pain treatments sales rose 15.1% to $79.7 million, helped by strong demand for its knee osteoarthritis injections

Surgical solutions sales rose 3.4% to $55.5 million, helped by higher U.S. demand for its bone graft products

BVS expects FY26 net sales of $600 million to $610 million, compared with estimates of $604.2 million

BVS shares were down more than 29% in 2025